請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84926
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭錦樺(Ching-Hua Kuo) | |
dc.contributor.author | Yi-Hsuan Chen | en |
dc.contributor.author | 陳易萱 | zh_TW |
dc.date.accessioned | 2023-03-19T22:33:07Z | - |
dc.date.copyright | 2022-10-05 | |
dc.date.issued | 2022 | |
dc.date.submitted | 2022-08-24 | |
dc.identifier.citation | 1. Li, J.; Zou, B.; Yeo, Y. H.; Feng, Y.; Xie, X.; Lee, D. H.; Fujii, H.; Wu, Y.; Kam, L. Y.; Ji, F.; Li, X.; Chien, N.; Wei, M.; Ogawa, E.; Zhao, C.; Wu, X.; Stave, C. D.; Henry, L.; Barnett, S.; Takahashi, H.; Furusyo, N.; Eguchi, Y.; Hsu, Y. C.; Lee, T. Y.; Ren, W.; Qin, C.; Jun, D. W.; Toyoda, H.; Wong, V. W.; Cheung, R.; Zhu, Q.; Nguyen, M. H., Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. The lancet. Gastroenterology & hepatology 2019, 4 (5), 389-398. 2. Chalasani, N.; Younossi, Z.; Lavine, J. E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S. A.; Brunt, E. M.; Sanyal, A. J., The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.) 2018, 67 (1), 328-357. 3. Llovet, J. M.; Kelley, R. K.; Villanueva, A.; Singal, A. G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R. S., Hepatocellular carcinoma. Nature reviews. Disease primers 2021, 7 (1), 6. 4. Tilg, H.; Adolph, T. E.; Moschen, A. R., Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology 2021, 73 (2), 833-842. 5. Banderas, D. Z.; Escobedo, J.; Gonzalez, E.; Liceaga, M. G.; Ramirez, J. C.; Castro, M. G., gamma-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol 2012, 24 (7), 805-10. 6. Chen, Z.; Tian, R.; She, Z.; Cai, J.; Li, H., Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020, 152, 116-141. 7. Deidda, M.; Piras, C.; Bassareo, P. P.; Cadeddu Dessalvi, C.; Mercuro, G., Metabolomics, a promising approach to translational research in cardiology. IJC Metabolic & Endocrine 2015, 9, 31-38. 8. Holmes, E.; Loo, R. L.; Stamler, J.; Bictash, M.; Yap, I. K.; Chan, Q.; Ebbels, T.; De Iorio, M.; Brown, I. J.; Veselkov, K. A.; Daviglus, M. L.; Kesteloot, H.; Ueshima, H.; Zhao, L.; Nicholson, J. K.; Elliott, P., Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008, 453 (7193), 396-400. 9. Tanaka, N.; Matsubara, T.; Krausz, K. W.; Patterson, A. D.; Gonzalez, F. J., Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012, 56 (1), 118-129. 10. Lake, A. D.; Novak, P.; Shipkova, P.; Aranibar, N.; Robertson, D. G.; Reily, M. D.; Lehman-McKeeman, L. D.; Vaillancourt, R. R.; Cherrington, N. J., Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 2015, 47 (3), 603-15. 11. Ferslew, B. C.; Xie, G.; Johnston, C. K.; Su, M.; Stewart, P. W.; Jia, W.; Brouwer, K. L. R.; Sidney Barritt, A., Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences 2015, 60 (11), 3318-3328. 12. Puri, P.; Daita, K.; Joyce, A.; Mirshahi, F.; Santhekadur, P. K.; Cazanave, S.; Luketic, V. A.; Siddiqui, M. S.; Boyett, S.; Min, H.-K.; Kumar, D. P.; Kohli, R.; Zhou, H.; Hylemon, P. B.; Contos, M. J.; Idowu, M.; Sanyal, A. J., The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 2018, 67 (2), 534-548. 13. Nimer, N.; Choucair, I.; Wang, Z.; Nemet, I.; Li, L.; Gukasyan, J.; Weeks, T. L.; Alkhouri, N.; Zein, N.; Tang, W. H. W.; Fischbach, M. A.; Brown, J. M.; Allayee, H.; Dasarathy, S.; Gogonea, V.; Hazen, S. L., Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism 2021, 116, 154457. 14. Lee, D. H.; Blomhoff, R.; Jacobs, D. R., Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radical Research 2004, 38 (6), 535-539. 15. Lim, J. S.; Yang, J. H.; Chun, B. Y.; Kam, S.; Jacobs, D. R.; Lee, D. H., Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic. Biol. Med. 2004, 37 (7), 1018-1023. 16. Yavuz, B. B.; Yavuz, B.; Halil, M.; Cankurtaran, M.; Ulger, Z.; Cankurtaran, E. S.; Aytemir, K.; Ariogul, S., Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer's disease. International Psychogeriatrics 2008, 20 (4), 815-823. 17. Pannala, V. R.; Estes, S. K.; Rahim, M.; Trenary, I.; O'Brien, T. P.; Shiota, C.; Printz, R. L.; Reifman, J.; Oyama, T.; Shiota, M.; Young, J. D.; Wallqvist, A., Mechanism-based identification of plasma metabolites associated with liver toxicity. Toxicology 2020, 441, 152493. 18. Wei, T.-Y. Development of analytical platforms for the detection of voriconazole-induced liver injury. National Taiwan University, 2014. 19. Pang, Z.; Chong, J.; Zhou, G.; de Lima Morais, D. A.; Chang, L.; Barrette, M.; Gauthier, C.; Jacques, P.-É.; Li, S.; Xia, J., MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Research 2021, 49 (W1), W388-W396. 20. van den Berg, R. A.; Hoefsloot, H. C. J.; Westerhuis, J. A.; Smilde, A. K.; van der Werf, M. J., Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 2006, 7 (1), 142. 21. Hsiao, J. J.; Potter, O. G.; Chu, T.-W.; Yin, H., Improved LC/MS Methods for the Analysis of Metal-Sensitive Analytes Using Medronic Acid as a Mobile Phase Additive. Analytical chemistry 2018, 90 (15), 9457-9464. 22. Ulvik, A.; McCann, A.; Midttun, Ø.; Meyer, K.; Godfrey, K. M.; Ueland, P. M., Quantifying Precision Loss in Targeted Metabolomics Based on Mass Spectrometry and Nonmatching Internal Standards. Analytical chemistry 2021, 93 (21), 7616-7624. 23. Psychogios, N.; Hau, D. D.; Peng, J.; Guo, A. C.; Mandal, R.; Bouatra, S.; Sinelnikov, I.; Krishnamurthy, R.; Eisner, R.; Gautam, B.; Young, N.; Xia, J.; Knox, C.; Dong, E.; Huang, P.; Hollander, Z.; Pedersen, T. L.; Smith, S. R.; Bamforth, F.; Greiner, R.; McManus, B.; Newman, J. W.; Goodfriend, T.; Wishart, D. S., The human serum metabolome. PLoS One 2011, 6 (2), e16957. 24. Dalle-Donne, I.; Rossi, R., Analysis of thiols. Journal of Chromatography B 2009, 877 (28), 3271-3273. 25. Russo, M. S. T.; Napylov, A.; Paquet, A.; Vuckovic, D., Comparison of N-ethyl maleimide and N-(1-phenylethyl) maleimide for derivatization of biological thiols using liquid chromatography-mass spectrometry. Analytical and bioanalytical chemistry 2020, 412 (7), 1639-1652. 26. Sun, X.; Heinrich, P.; Berger, R. S.; Oefner, P. J.; Dettmer, K., Quantification and (13)C-Tracer analysis of total reduced glutathione by HPLC-QTOFMS/MS. Anal Chim Acta 2019, 1080, 127-137. 27. Matés, J. M.; Pérez-Gómez, C.; de Castro, I. N.; Asenjo, M.; Márquez, J., Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. The International Journal of Biochemistry & Cell Biology 2002, 34 (5), 439-458. 28. Newsholme, P.; Procopio, J.; Lima, M. M. R.; Pithon-Curi, T. C.; Curi, R., Glutamine and glutamate—their central role in cell metabolism and function. Cell Biochemistry and Function 2003, 21 (1), 1-9. 29. Wu, S. L.; Wei, T. Y.; Lin, S. W.; Su, K. Y.; Kuo, C. H., Metabolomics Investigation of Voriconazole-Induced Hepatotoxicity in Mice. Chem Res Toxicol 2019, 32 (9), 1840-1849. 30. Wu, S. L.; Cheng, C. N.; Wang, C. C.; Lin, S. W.; Kuo, C. H., Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. Toxicol Appl Pharmacol 2020, 403, 115157. 31. Bahri, S.; Zerrouk, N.; Aussel, C.; Moinard, C.; Crenn, P.; Curis, E.; Chaumeil, J.-C.; Cynober, L.; Sfar, S., Citrulline: From metabolism to therapeutic use. Nutrition 2013, 29 (3), 479-484. 32. Tewari, D.; Sah, A. N.; Bawari, S.; Nabavi, S. F.; Dehpour, A. R.; Shirooie, S.; Braidy, N.; Fiebich, B. L.; Vacca, R. A.; Nabavi, S. M., Role of Nitric Oxide in Neurodegeneration: Function, Regulation, and Inhibition. Curr Neuropharmacol 2021, 19 (2), 114-126. 33. Holeček, M., Histidine in Health and Disease: Metabolism, Physiological Importance, and Use as a Supplement. Nutrients 2020, 12 (3). 34. Karkucinska-Wieckowska, A.; Simoes, I. C. M.; Kalinowski, P.; Lebiedzinska-Arciszewska, M.; Zieniewicz, K.; Milkiewicz, P.; Gorska-Ponikowska, M.; Pinton, P.; Malik, A. N.; Krawczyk, M.; Oliveira, P. J.; Wieckowski, M. R., Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. European Journal of Clinical Investigation 2022, 52 (3). 35. Whitfield, J. B., Gamma glutamyl transferase. Critical Reviews in Clinical Laboratory Sciences 2001, 38 (4), 263-355. 36. Lu, S. C., Glutathione synthesis. Biochim Biophys Acta 2013, 1830 (5), 3143-53. 37. Chiang, J. Y., Bile acid metabolism and signaling. Compr Physiol 2013, 3 (3), 1191-212. 38. Arab, J. P.; Karpen, S. J.; Dawson, P. A.; Arrese, M.; Trauner, M., Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 2017, 65 (1), 350-362. 39. Gilmore, I. T.; Hofmann, A. F., Altered drug metabolism and elevated serum bile acids in liver disease: a unified pharmacokinetic explanation. Gastroenterology 1980, 78 (1), 177-9. 40. Kim, M. J.; Suh, D. J., Profiles of serum bile acids in liver diseases. Korean J Intern Med 1986, 1 (1), 37-42. 41. Wu, S. L.; Cheng, C. N.; Wang, C. C.; Lin, S. W.; Kuo, C. H., Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. Toxicology and Applied Pharmacology 2020, 403. 42. Gottlieb, A.; Bechmann, L.; Canbay, A., The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids. Ann Hepatol 2018, 17 (3), 340-341. 43. Wegermann, K.; Howe, C.; Henao, R.; Wang, Y.; Guy, C. D.; Abdelmalek, M. F.; Diehl, A. M.; Moylan, C. A., Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021, 5 (4), 608-617. 44. Radun, R.; Trauner, M., Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Seminars in Liver Disease 2021, 41 (04), 461-475. 45. Neuschwander-Tetri, B. A.; Loomba, R.; Sanyal, A. J.; Lavine, J. E.; Van Natta, M. L.; Abdelmalek, M. F.; Chalasani, N.; Dasarathy, S.; Diehl, A. M.; Hameed, B.; Kowdley, K. V.; McCullough, A.; Terrault, N.; Clark, J. M.; Tonascia, J.; Brunt, E. M.; Kleiner, D. E.; Doo, E.; Nash Clin Res, N., Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385 (9972), 956-965. 46. Younossi, Z. M.; Ratziu, V.; Loomba, R.; Rinella, M.; Anstee, Q. M.; Goodman, Z.; Bedossa, P.; Geier, A.; Beckebaum, S.; Newsome, P. N.; Sheridan, D.; Sheikh, M. Y.; Trotter, J.; Knapple, W.; Lawitz, E.; Abdelmalek, M. F.; Kowdley, K. V.; Montano-Loza, A. J.; Boursier, J.; Mathurin, P.; Bugianesi, E.; Mazzella, G.; Olveira, A.; Cortez-Pinto, H.; Graupera, I.; Orr, D.; Gluud, L. L.; Dufour, J. F.; Shapiro, D.; Campagna, J.; Zaru, L.; MacConell, L.; Shringarpure, R.; Harrison, S.; Sanyal, A. J.; Investigators, R. S., Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019, 394 (10215), 2184-2196. 47. Deng, P.; Barney, J.; Petriello, M. C.; Morris, A. J.; Wahlang, B.; Hennig, B., Hepatic metabolomics reveals that liver injury increases PCB 126-induced oxidative stress and metabolic dysfunction. Chemosphere 2019, 217, 140-149. 48. Wu, G.; Fang, Y. Z.; Yang, S.; Lupton, J. R.; Turner, N. D., Glutathione metabolism and its implications for health. J Nutr 2004, 134 (3), 489-92. 49. Hanigan, M. H., Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res 2014, 122, 103-41. 50. Cui, L.; Jiang, X.; Zhao, L.; Chen, Y.; Cheng, Z.; Li, J.; Tan, W.; Chen, A. F., Cysteinylglycine for potential diagnosis of extrahepatic cholangiocarcinoma using a novel metabolomic approach. Translational Cancer Research 2018, 7 (1), 68-78. 51. Singer, M.; Deutschman, C. S.; Seymour, C. W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G. R.; Chiche, J. D.; Coopersmith, C. M.; Hotchkiss, R. S.; Levy, M. M.; Marshall, J. C.; Martin, G. S.; Opal, S. M.; Rubenfeld, G. D.; van der Poll, T.; Vincent, J. L.; Angus, D. C., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315 (8), 801-10. 52. Marshall, J. C.; Vincent, J.-L.; Guyatt, G.; Angus, D. C.; Abraham, E.; Bernard, G.; Bombardier, C.; Calandra, T.; Jørgensen, H. S.; Sylvester, R.; Boers, M., Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Critical Care Medicine 2005, 33 (8). 53. Youle, R. J.; van der Bliek, A. M., Mitochondrial fission, fusion, and stress. Science 2012, 337 (6098), 1062-5. 54. Dunn, J. D.; Alvarez, L. A. J.; Zhang, X. Z.; Soldati, T., Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biology 2015, 6, 472-485. 55. Brealey, D.; Brand, M.; Hargreaves, I.; Heales, S.; Land, J.; Smolenski, R.; Davies, N. A.; Cooper, C. E.; Singer, M., Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002, 360 (9328), 219-23. 56. Khovidhunkit, W.; Kim, M. S.; Memon, R. A.; Shigenaga, J. K.; Moser, A. H.; Feingold, K. R.; Grunfeld, C., Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45 (7), 1169-96. 57. Tappy, L.; Chiolero, R., Substrate utilization in sepsis and multiple organ failure. Critical Care Medicine 2007, 35 (9), S531-S534. 58. Crouser, E. D., Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 2004, 4 (5-6), 729-41. 59. Singer, M., The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 2014, 5 (1), 66-72. 60. Japiassú, A. M.; Santiago, A. P.; d'Avila, J. C.; Garcia-Souza, L. F.; Galina, A.; Castro Faria-Neto, H. C.; Bozza, F. A.; Oliveira, M. F., Bioenergetic failure of human peripheral blood monocytes in patients with septic shock is mediated by reduced F1Fo adenosine-5'-triphosphate synthase activity. Crit Care Med 2011, 39 (5), 1056-63. 61. Liu, Z.; Yin, P.; Amathieu, R.; Savarin, P.; Xu, G., Application of LC-MS-based metabolomics method in differentiating septic survivors from non-survivors. Analytical and bioanalytical chemistry 2016, 408 (27), 7641-7649. 62. Chung, K. P.; Chen, G. Y.; Chuang, T. Y.; Huang, Y. T.; Chang, H. T.; Chen, Y. F.; Liu, W. L.; Chen, Y. J.; Hsu, C. L.; Huang, M. T.; Kuo, C. H.; Yu, C. J., Increased Plasma Acetylcarnitine in Sepsis Is Associated With Multiple Organ Dysfunction and Mortality: A Multicenter Cohort Study. Critical Care Medicine 2019, 47 (2), 210-218. 63. Nanni, G.; Pittiruti, M.; Giovannini, I.; Boldrini, G.; Ronconi, P.; Castagneto, M., Plasma carnitine levels and urinary carnitine excretion during sepsis. JPEN J Parenter Enteral Nutr 1985, 9 (4), 483-90. 64. Mickiewicz, B.; Tam, P.; Jenne, C. N.; Leger, C.; Wong, J.; Winston, B. W.; Doig, C.; Kubes, P.; Vogel, H. J., Integration of metabolic and inflammatory mediator profiles as a potential prognostic approach for septic shock in the intensive care unit. Crit Care 2015, 19 (1), 11. 65. Garcia-Alvarez, M.; Marik, P.; Bellomo, R., Sepsis-associated hyperlactatemia. Critical Care 2014, 18 (5). 66. Mikkelsen, M. E.; Miltiades, A. N.; Gaieski, D. F.; Goyal, M.; Fuchs, B. D.; Shah, C. V.; Bellamy, S. L.; Christie, J. D., Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med 2009, 37 (5), 1670-7. 67. Carré, J. E.; Orban, J. C.; Re, L.; Felsmann, K.; Iffert, W.; Bauer, M.; Suliman, H. B.; Piantadosi, C. A.; Mayhew, T. M.; Breen, P.; Stotz, M.; Singer, M., Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 2010, 182 (6), 745-51. 68. Martinez-Reyes, I.; Chandel, N. S., Mitochondrial TCA cycle metabolites control physiology and disease. Nature Communications 2020, 11 (1). 69. Vincent, J. L.; Moreno, R.; Takala, J.; Willatts, S.; De Mendonça, A.; Bruining, H.; Reinhart, C. K.; Suter, P. M.; Thijs, L. G., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22 (7), 707-10. 70. Dellinger, R. P.; Levy, M. M.; Rhodes, A.; Annane, D.; Gerlach, H.; Opal, S. M.; Sevransky, J. E.; Sprung, C. L.; Douglas, I. S.; Jaeschke, R.; Osborn, T. M.; Nunnally, M. E.; Townsend, S. R.; Reinhart, K.; Kleinpell, R. M.; Angus, D. C.; Deutschman, C. S.; Machado, F. R.; Rubenfeld, G. D.; Webb, S. A.; Beale, R. J.; Vincent, J. L.; Moreno, R., Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41 (2), 580-637. 71. Ranieri, V. M.; Rubenfeld, G. D.; Thompson, B. T.; Ferguson, N. D.; Caldwell, E.; Fan, E.; Camporota, L.; Slutsky, A. S., Acute respiratory distress syndrome: the Berlin Definition. Jama 2012, 307 (23), 2526-33. 72. Hoffmann, G. F.; Meier-Augenstein, W.; Stöckler, S.; Surtees, R.; Rating, D.; Nyhan, W. L., Physiology and pathophysiology of organic acids in cerebrospinal fluid. J Inherit Metab Dis 1993, 16 (4), 648-69. 73. Wasyluk, W.; Zwolak, A., Metabolic Alterations in Sepsis. Journal of Clinical Medicine 2021, 10 (11). 74. Kamisoglu, K.; Haimovich, B.; Calvano, S. E.; Coyle, S. M.; Corbett, S. A.; Langley, R. J.; Kingsmore, S. F.; Androulakis, I. P., Human metabolic response to systemic inflammation: assessment of the concordance between experimental endotoxemia and clinical cases of sepsis/SIRS. Critical Care 2015, 19. 75. Tuytten, R.; Lemière, F.; Witters, E.; Dongen, W. V.; Slegers, H.; Newton, R. P.; Onckelen, H. V.; Esmans, E. L., Stainless steel electrospray probe: A dead end for phosphorylated organic compounds? Journal of Chromatography A 2006, 1104 (1), 209-221. 76. Cheryl Boissel, T. H. W., Improved Peak Shape and Wide Selectivity Range with ACQUITY Premier Columns. Waters Application Note 2020. 77. Kenneth D. Berthelette, S. S., Increased Peak Recovery and Peak Shape of Phosphorylated Compounds Using ACQUITY PREMIER and XBridge PREMIER Columns Compared to Stainless-Steel Columns. Waters Application Note 2021. 78. Robert E. Birdsall, J. K., Samantha Ippoliti, Ying Qing Yu, Increasing Recovery and Chromatographic Performance of “Acidic” Peptides Using Waters ACQUITY PREMIER Solution. Waters Application Note 2021. 79. McKinnon, W.; Lord, G. A.; Forni, L. G.; Peron, J. M.; Hilton, P. J., A rapid LC-MS method for determination of plasma anion profiles of acidotic patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006, 833 (2), 179-85. 80. Tsai, C. S., Spontaneous decarboxylation of oxalacetic acid. Canadian Journal of Chemistry 1967, 45 (8), 873-880. 81. Jaurila, H.; Koivukangas, V.; Koskela, M.; Gäddnäs, F.; Myllymaa, S.; Kullaa, A.; Salo, T.; Ala-Kokko, T. I., (1)H NMR Based Metabolomics in Human Sepsis and Healthy Serum. Metabolites 2020, 10 (2). 82. Poulose, V.; Koh, J.; Ren, T. T.; Siang, W. H.; Wee, I.; Hwei, H. H.; Wen, K. J., A randomized pilot study of parenteral glutamine supplementation in severe sepsis. Critical care and shock 2017, 20 (3), 61‐67. 83. Xiao, D.; Zeng, L.; Yao, K.; Kong, X.; Wu, G.; Yin, Y., The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications. Amino Acids 2016, 48 (9), 2067-80. 84. Stevens, V. L.; Hoover, E.; Wang, Y.; Zanetti, K. A., Pre-Analytical Factors that Affect Metabolite Stability in Human Urine, Plasma, and Serum: A Review. Metabolites 2019, 9 (8), 156. 85. Elmassry, M. M.; Mudaliar, N. S.; Colmer-Hamood, J. A.; San Francisco, M. J.; Griswold, J. A.; Dissanaike, S.; Hamood, A. N., New markers for sepsis caused by Pseudomonas aeruginosa during burn infection. Metabolomics 2020, 16 (3). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84926 | - |
dc.description.abstract | 代謝體學是透過全盤分析生物系統(細胞、組織、器官、體液或生物體)中代謝物的科學研究,可代表體內複雜生物系統之間的整體相互作用,並更直接反映表現型。代謝體學在研究病理機制和辨別疾病的潛在生物標誌已成為潛力領域,其中標的代謝體學是對特定代謝物進行定量分析的方法。在本論文中,我們使用標的代謝體學,透過選擇測量不同代謝途徑中的數個代謝物來回答臨床問題。考量本研究標的分析物的極性,我們使用親水性作用液相層析結合質譜儀來分析。 在本論文的第一部分,我們探討非酒精性脂肪性肝炎(non-alcoholic steatohepatitis, NASH)患者單獨丙麩胺酸轉移酶(γ-glutamyl transferase, GGT)升高和氧化壓力的相關性。非酒精性脂肪肝炎是屬於一種嚴重的非酒精性脂肪肝疾病(non-alcoholic fatty liver disease, NAFLD),其特徵為肝內脂肪堆積合併壞死性發炎,可能惡化為嚴重纖維化與肝癌。氧化壓力被認為是 NASH 的致病原因,在 NASH 病人中經常觀察到GGT單獨上升的情形。GGT 已被提出作為 NASH 患者進展為纖維化的標誌。然而,分子機轉層面的機制尚未被清楚地了解。本研究開發了液相層析串聯質譜儀方法來測量人體血清中的氧化壓力代謝物,分析了 NASH 患者血清中的代謝物,並將 GGT 升高的 NASH 患者(n=60)與 GGT 正常的 NASH 患者(n=44)進行了比較。研究結果顯示,在 GGT 升高組中有較低的t-cysteinylglycine和較高的glutathione前驅物,包括glutamic acid、cystine和glycine。此外,glutamine與glutamate的比值在GGT上升組與GGT正常組相比顯著降低(p = 0.014),顯示出glutamine被轉換成為glutamate,以增加glutathione的生成來調節氧化壓力。這些結果顯示GGT升高的NASH患者體內確實有較高的氧化壓力,為 NASH 研究提供更深入的機制資訊。 在第二部分中,我們研究了血漿三羧酸循環(TCA cycle)相關代謝物濃度與敗血症多重器官衰竭嚴重程度之間的關係。敗血症是由於宿主對感染的反應失調而導致的急性器官衰竭的嚴重疾病。過去的研究提出,生物能量受到干擾後會導致與敗血症相關的多重器官衰竭。TCA cycle由多個單向酵素反應組成,是真核細胞產生能量的基礎。然而,目前尚不清楚TCA cycle受損是否影響敗血症相關器官衰竭進展。在本研究中,我們應用LC-MS/MS標的代謝體學方法來測量血漿中TCA cycle代謝物,並研究 TCA cycle代謝物的血中濃度是否與敗血症器官衰竭的嚴重度相關。我們的研究結果顯示,敗血症造成的器官衰竭與malate累積和下游代謝物包括citrate/isocitrate和cis-aconitate無改變有關。我們指出citrate synthase缺乏可能與敗血症器官衰竭的發展有關。這項研究提供了對敗血症器官衰竭的分子機轉資訊,並支持未來的機轉研究。 總結,本論文成功使用標的代謝體學方法研究 NASH患者的血清代謝物和敗血症患者血漿中的TCA cycle代謝物,提供了對這兩種疾病分子機制的重要資訊。 | zh_TW |
dc.description.abstract | Metabolomics is a scientific study through a comprehensive analysis of metabolites in a biological system (cell, tissue, organ, biological fluid, or organism). Metabolomics could represent the overall interactions between whole complex biosystems in the body and be more direct in reflecting the phenotype. Metabolomics has become a promising area for investigating pathological mechanism and identifying potential biomarkers of diseases. Targeted metabolomics is a quantitative approach to evaluate a set of selected metabolites. In this thesis, we used targeted metabolomics methods by selecting several metabolites in different metabolic pathways to answer the clinical problem. Considering the polar properties of target analytes, a hydrophilic interaction liquid chromatography coupled with mass spectrometry was used in this study. In the first part of this thesis, we investigated the association of isolated γ-glutamyltransferase (GGT) elevation and oxidative stress in patients with nonalcoholic steatohepatitis (NASH). NASH, the inflammatory subtype of nonalcoholic fatty liver disease, may deteriorate into advanced fibrosis and liver cancer, leading to substantial medical burdens. Oxidative stress is considered the major pathogenic determinant of NASH, and isolated GGT elevation is frequently observed in NASH patients. GGT has been proposed as a marker for fibrosis progression in NASH patients. However, specific molecular mechanisms are not yet clearly understood. We developed LC-MS/MS methods to comprehensively analyze metabolites associated with oxidative stress in human serum. The serum metabolic patterns in NASH patients were analyzed, and NASH patients with isolated GGT elevation (n = 60) were compared with NASH patients with normal GGT (n = 44). This study showed a significantly lower t-cysteinylglycine and higher glutathione (GSH) precursors, including glutamic acid, cystine, and glycine, are present in the GGT elevation group. Moreover, a significantly lower glutamine-to-glutamate ratio (p = 0.014) in the GGT elevation group implies the transformation of glutamine to glutamate was also increased to produce more GSH to relieve oxidative stress. The findings uncover the oxidative stress in NASH patients with isolated GGT elevation and provide mechanism insights into NASH progression. In the second part, we investigated the association between the plasma level of tricarboxylic acid cycle (TCA cycle)-related metabolites and the severity of multiple organ dysfunction in sepsis. Sepsis is a life-threatening disease featured by acute organ dysfunction due to dysregulated host responses to infection. Previous studies suggested that perturbed bioenergetics lead to sepsis-related multi-organ dysfunction. TCA cycle, constituted by multiple unidirectional enzymatic reactions, is responsible for energy production in eukaryotic cells. However, it is unclear whether impaired TCA cycle underlies the development of sepsis-related organ dysfunction. In this study, we applied an LC-MS/MS-based targeted metabolomics method to measure metabolites in the TCA cycle and investigated whether the levels of TCA cycle-related metabolites are associated with the severity of organ dysfunction in sepsis. Our results demonstrated that sepsis-related organ dysfunction is associated with malate accumulation and unaltered downstream metabolites, including citrate/isocitrate and cis-aconitate. In addition, we pointed out that deficiency of citrate synthase may be related to the development of organ dysfunction in sepsis. This study provides mechanistic insights into sepsis-related organ dysfunction and supports future mechanistic translational studies. In conclusion, these two studies successfully used targeted metabolomics methods to investigate GGT elevation in NASH and TCA cycle-related metabolites in sepsis. The results provide mechanistic insights into these two diseases. | en |
dc.description.provenance | Made available in DSpace on 2023-03-19T22:33:07Z (GMT). No. of bitstreams: 1 U0001-2308202213182900.pdf: 4331090 bytes, checksum: 8c37037e1cb0a0954ec500995e9e81aa (MD5) Previous issue date: 2022 | en |
dc.description.tableofcontents | Contents 誌謝 i 中文摘要 ii Abstract iv Part I: Investigating the role of isolated γ-glutamyltransferase elevation and oxidative stress in patients with non-alcoholic steatohepatitis 1 1. Introduction 2 2. Method 4 2.1 Study design 4 2.2 Metabolomics analysis 5 2.3 Analysis of endogenous thiols 8 2.4 LC/MS data processing and statistical analysis 10 3. Result 11 3.1 Development of the UHPLC-MS/MS method for target analytes 11 3.2 Optimization of sample preparation 12 3.3 Evaluated the linearity of spiking concentration and signal intensity 12 3.4 LC-MS/MS analysis of plasma total thiols 13 3.5 Investigating the role of isolated GGT elevation and oxidative stress in patients with non-alcoholic steatohepatitis 15 4. Discussion 17 4.1 Improve the precision in targeted metabolomics 17 4.2 Plasma total thiols analysis 18 4.3 Stability issue of NEM derivatization thiols 18 4.4 Investigating the role of isolated GGT elevation and oxidative stress in patients with NASH 19 5. Conclusion 24 6. Figures 25 7. Tables 42 Part II: Investigating the association between plasma level of tricarboxylic acid cycle metabolites and the severity of multiple organ dysfunction in sepsis 54 1. Introduction 55 2. Materials and Methods 57 2.1 Chemicals materials and stock solutions 57 2.2 Sample preparation 57 2.3 UHPLC-MS/MS 58 2.4 Clinical application 58 3. Results 61 3.1 Development of the UHPLC-MS/MS method 61 3.2 Optimization of sample preparation and evaluated the linearity 62 3.3 Clinical application 62 4. Discussions 64 4.1 The challenge of analyzing TCA cycle-related metabolites in LC-MS/MS 64 4.2 The association between circulatory TCA cycle metabolome and the severity of multi-organ dysfunction in sepsis 65 5. Conclusion 67 6. Figures 69 7. Tables 76 References 81 Figure contents Part I: Investigating the role of isolated γ-glutamyltransferase elevation and oxidative stress in patients with non-alcoholic steatohepatitis Figure 1. LC-MS/MS chromatogram in positive mode in a pooled human plasma extract under the optimized method. 27 Figure 2. LC-MS/MS chromatogram of 11 target metabolites and 3 SIL-IS in negative mode in a pooled human plasma extract under the optimized method. 28 Figure 3. Comparison of dilution fold on the signal intensity of target metabolites without ISTD correction. 29 Figure 4. Spiking standard solutions into plasma samples to evaluate the linearity of target analytes 31 Figure 5. The linearity of target analytes after ISTD correction. 32 Figure 6. Effects of DTT reduction reaction temperature and time on the signal intensity. 33 Figure 7. Effects of NEM derivatization concentration on the signal intensity. 33 Figure 8. MRM chromatogram of NEM derivatization thiols in amide column under the optimized method 34 Figure 9.Twenty-five hours stability of NEM derivatization at 4°C with different antioxidants and 1μg mL-1 FA. 35 Figure 10.Twenty-five hours stability of NEM derivatization thiols at 4°C after SIL-IS correction. 36 Figure 11.(a) PLS-DA plot of normal GGT and GGT elevation group, and VIP score of (b) component 1 and (c) component 2. 37 Figure 12.Box plots of 10 metabolites with significant differences between two groups. 38 Figure 13.Box plot of glutamine-to-glutamate ratios between two groups. 39 Figure 14.Correlation between serum GGT levels and metabolites. 40 Figure 15.Proposed mechanism of NASH with isolated GGT elevation and the role of oxidative stress. 41 Part II: Investigating the association between plasma level of tricarboxylic acid cycle metabolites and the severity of multiple organ dysfunction in sepsis Figure 1. LC-MS/MS chromatogram of the (a) standard solution and (b) pooled human plasma extract under the optimized method. 69 Figure 2. The MRM chromatogram of 10μg mL-1 citrate and isocitrate solution with transitions of (a) m/z 191→173, (b) m/z 191→87, (c) m/z 191→111 70 Figure 3. Comparison of dilution fold on the signal intensity of TCA cycle metabolites. 71 Figure 4. Spiking standard solutions into plasma samples to evaluate the linearity of target analytes. 72 Figure 5. Plasma profiles of TCA cycle-related metabolites suggest blockade at the step of citrate synthase is associated with organ dysfunction in sepsis. 73 Figure 6. Plasma profiles of TCA cycle-related metabolites in the study cohort are associated with sepsis-related acute kidney injury (AKI). 74 Figure 7. Plasma profiles of TCA cycle-related metabolites in the study cohort are not associated with sepsis-related cardiovascular dysfunction 75 Table contents Part I: Investigating the role of isolated γ-glutamyltransferase elevation and oxidative stress in patients with non-alcoholic steatohepatitis Table 1. The positive mode MRM transitions and their respective pathways of target metabolites and internal standards 42 Table 2. The negative mode MRM transitions and their respective pathways of target metabolites and internal standards 48 Table 3. The MRM transitions of endogenous thiol and internal standards in positive mode 49 Table 4. Clinical characteristics of the study cohort 50 Table 5. Univariate analysis result of target metabolites between GGT elevation group and the normal GGT group 51 Table 6. Significantly changed metabolites (p value < 0.05) in NASH patients comparing isolated GGT elevation and normal GGT 53 Part II: Investigating the association between plasma level of tricarboxylic acid cycle metabolites and the severity of multiple organ dysfunction in sepsis Table 1. MRM transition of TCA cycle metabolites 76 Table 2. Continuous variables adjusted for age and gender through linear regression models 77 Table 3. Clinical characteristics of the study cohort 78 Table 4. Correlation between plasma level of TCA cycle metabolites and sepsis-related organ dysfunction 79 | |
dc.language.iso | en | |
dc.title | 以標的代謝體學方法結合親水性作用液相層析質譜儀進行臨床應用 第一部分:探討非酒精性脂肪肝炎患者之單獨丙麩胺酸轉移酶上升與氧化壓力的角色 第二部分:探討血漿中三羧酸循環代謝物與敗血症多重器官衰竭嚴重度之相關性 | zh_TW |
dc.title | Using targeted metabolomics approach and hydrophilic interaction liquid chromatography coupled with mass spectrometry for clinical application Part I: Investigating the role of isolated γ-glutamyltransferase elevation and oxidative stress in patients with non-alcoholic steatohepatitis Part II: Investigating the association between plasma level of tricarboxylic acid cycle metabolites and the severity of multiple organ dysfunction in sepsis | en |
dc.type | Thesis | |
dc.date.schoolyear | 110-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 鐘桂彬(Kuei-Pin Chung) | |
dc.contributor.oralexamcommittee | 楊宏志(Hung-Chih Yang),廖曉偉(Hsiao-Wei Liao) | |
dc.subject.keyword | 代謝體學,氧化壓力,丙麩胺酸轉移酶,非酒精性脂肪性肝炎,敗血症,三羧酸循環, | zh_TW |
dc.subject.keyword | metabolomics,oxidative stress,GGT,NASH,sepsis,TCA cycle, | en |
dc.relation.page | 86 | |
dc.identifier.doi | 10.6342/NTU202202695 | |
dc.rights.note | 同意授權(限校園內公開) | |
dc.date.accepted | 2022-08-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
dc.date.embargo-lift | 2027-08-23 | - |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2308202213182900.pdf 目前未授權公開取用 | 4.23 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。